A global medtech company, iCAD Inc., has announced a strategic commercial agreement with Radiology Partners, the nation’s largest radiology practice. The agreement positions iCAD as Radiology Partners’ breast AI provider, expanding potential for iCAD’s technology to reach millions of women in the U.S. Photo credit: Getty Images.
July 26, 2023 – iCAD, Inc., a global medical technology provider of innovative cancer detection and therapy solutions, announced it has signed a new strategic multi- year commercial agreement with Radiology Partners, the nation’s largest radiology practice through its owned and affiliated practices.
Under the agreement, which was executed on June 27 and detailed in a July 19 statement from the Nashua, NH-based iCAD, Radiology Partners selected iCAD as its provider of breast AI technologies deployed through the Radiology Partners Cloud. This will allow iCAD to leverage Radiology Partners’ clinical expertise, AI validation platform, scale, and leadership position to expand access to the Company’s Breast AI Suite to thousands of physicians and millions of patients.
“We were pleased to join forces with Radiology Partners in November 2022, and the finalization of this commercial agreement marks a meaningful milestone in our collective mission to transform radiology by improving the workflow for providers and outcomes for patients,” said Dana Brown, President and CEO of iCAD, Inc.
Radiology Partners, through its owned and affiliated practices, is the largest radiology practice in the U.S. Recognized for clinical leadership in mammography screening, the physician- led and physician-owned practice, serves more than 3,200 hospitals and other healthcare facilities across the nation, including 17 of the 20 largest health systems in the country, according to the iCAD statement.
Nina Kottler, MD, MS, Associate CMO for Clinical Artificial Intelligence at Radiology Partners, said this of the agreement:
“The execution of this agreement represents an exciting step forward for Radiology Partners and the patients we serve, and aligns with RP’s vision to partner with the best AI companies in the world. iCAD’s suite of AI solutions is transforming the standard of care in mammography screening, and the body of evidence supporting this technology is already generating interest and demand across our network. New research from one of our sites recently presented at the European Congress of Radiology (ECR) meeting in March demonstrated ProFound AI increased breast cancer detection by 23 percent, without increasing the rate of false positives.1 We look forward to continuing to partner closely with iCAD to expand on our shared mission to take on one of the greatest threats to women’s health nationwide.”
More information: www.icadmed.com
1. Schilling K. Real-world breast cancer screening performance with digital breast tomosynthesis before and after implementation of an artificial intelligence detection system. Research presentation session presented at the European Congress of Radiology (ECR) meeting; March 1-5, 2023; Vienna, Austria.
February 13, 2026 
